450 related articles for article (PubMed ID: 27856634)
21. Enhancement of antibody-dependent cell-mediated cytotoxicity by endowing IgG with FcαRI (CD89) binding.
Borrok MJ; Luheshi NM; Beyaz N; Davies GC; Legg JW; Wu H; Dall'Acqua WF; Tsui P
MAbs; 2015; 7(4):743-51. PubMed ID: 25970007
[TBL] [Abstract][Full Text] [Related]
22. Generation and characterization of a high-affinity chimeric anti-OX40 antibody with potent antitumor activity.
Yang Y; Chai X; Xin W; Wang D; Dai C; Qian F; Yang T
FEBS Lett; 2021 Jun; 595(11):1587-1603. PubMed ID: 33792041
[TBL] [Abstract][Full Text] [Related]
23. Novel asymmetrically engineered antibody Fc variant with superior FcγR binding affinity and specificity compared with afucosylated Fc variant.
Mimoto F; Igawa T; Kuramochi T; Katada H; Kadono S; Kamikawa T; Shida-Kawazoe M; Hattori K
MAbs; 2013; 5(2):229-36. PubMed ID: 23406628
[TBL] [Abstract][Full Text] [Related]
24. Inhibitory Fcγ receptor engagement drives adjuvant and anti-tumor activities of agonistic CD40 antibodies.
Li F; Ravetch JV
Science; 2011 Aug; 333(6045):1030-4. PubMed ID: 21852502
[TBL] [Abstract][Full Text] [Related]
25. Fc Engineering of Human IgG1 for Altered Binding to the Neonatal Fc Receptor Affects Fc Effector Functions.
Grevys A; Bern M; Foss S; Bratlie DB; Moen A; Gunnarsen KS; Aase A; Michaelsen TE; Sandlie I; Andersen JT
J Immunol; 2015 Jun; 194(11):5497-508. PubMed ID: 25904551
[TBL] [Abstract][Full Text] [Related]
26. Development of a robust reporter-based ADCC assay with frozen, thaw-and-use cells to measure Fc effector function of therapeutic antibodies.
Cheng ZJ; Garvin D; Paguio A; Moravec R; Engel L; Fan F; Surowy T
J Immunol Methods; 2014 Dec; 414():69-81. PubMed ID: 25086226
[TBL] [Abstract][Full Text] [Related]
27. FcγRΙΙB controls the potency of agonistic anti-TNFR mAbs.
White AL; Chan HT; French RR; Beers SA; Cragg MS; Johnson PW; Glennie MJ
Cancer Immunol Immunother; 2013 May; 62(5):941-8. PubMed ID: 23543215
[TBL] [Abstract][Full Text] [Related]
28. Regulation of Monoclonal Antibody Immunotherapy by FcγRIIB.
Stopforth RJ; Cleary KL; Cragg MS
J Clin Immunol; 2016 May; 36 Suppl 1():88-94. PubMed ID: 26922075
[TBL] [Abstract][Full Text] [Related]
29. Identification of antibody glycosylation structures that predict monoclonal antibody Fc-effector function.
Chung AW; Crispin M; Pritchard L; Robinson H; Gorny MK; Yu X; Bailey-Kellogg C; Ackerman ME; Scanlan C; Zolla-Pazner S; Alter G
AIDS; 2014 Nov; 28(17):2523-30. PubMed ID: 25160934
[TBL] [Abstract][Full Text] [Related]
30. Fc Glyco- and Fc Protein-Engineering: Design of Antibody Variants with Improved ADCC and CDC Activity.
Kellner C; Derer S; Klausz K; Rosskopf S; Wirt T; Rösner T; Otte A; Cappuzzello E; Peipp M
Methods Mol Biol; 2018; 1827():381-397. PubMed ID: 30196508
[TBL] [Abstract][Full Text] [Related]
31. Structural characterization of GASDALIE Fc bound to the activating Fc receptor FcγRIIIa.
Ahmed AA; Keremane SR; Vielmetter J; Bjorkman PJ
J Struct Biol; 2016 Apr; 194(1):78-89. PubMed ID: 26850169
[TBL] [Abstract][Full Text] [Related]
32. Fc Binding by FcγRIIa Is Essential for Cellular Activation by the Anti-FcγRIIa mAbs 8.26 and 8.2.
Wines BD; Trist HM; Esparon S; Impey RE; Mackay GA; Andrews RK; Soares da Costa TP; Pietersz GA; Baker RI; Hogarth PM
Front Immunol; 2021; 12():666813. PubMed ID: 34759915
[TBL] [Abstract][Full Text] [Related]
33. Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functions.
Moore GL; Chen H; Karki S; Lazar GA
MAbs; 2010; 2(2):181-9. PubMed ID: 20150767
[TBL] [Abstract][Full Text] [Related]
34. Humanised IgG1 antibody variants targeting membrane-bound carcinoembryonic antigen by antibody-dependent cellular cytotoxicity and phagocytosis.
Ashraf SQ; Umana P; Mössner E; Ntouroupi T; Brünker P; Schmidt C; Wilding JL; Mortensen NJ; Bodmer WF
Br J Cancer; 2009 Nov; 101(10):1758-68. PubMed ID: 19904275
[TBL] [Abstract][Full Text] [Related]
35. Fc-engineered EGF-R antibodies mediate improved antibody-dependent cellular cytotoxicity (ADCC) against KRAS-mutated tumor cells.
Schlaeth M; Berger S; Derer S; Klausz K; Lohse S; Dechant M; Lazar GA; Schneider-Merck T; Peipp M; Valerius T
Cancer Sci; 2010 May; 101(5):1080-8. PubMed ID: 20331636
[TBL] [Abstract][Full Text] [Related]
36. Antitumor activities of agonistic anti-TNFR antibodies require differential FcγRIIB coengagement in vivo.
Li F; Ravetch JV
Proc Natl Acad Sci U S A; 2013 Nov; 110(48):19501-6. PubMed ID: 24218606
[TBL] [Abstract][Full Text] [Related]
37. The impact of Fc engineering on an anti-CD19 antibody: increased Fcgamma receptor affinity enhances B-cell clearing in nonhuman primates.
Zalevsky J; Leung IW; Karki S; Chu SY; Zhukovsky EA; Desjarlais JR; Carmichael DF; Lawrence CE
Blood; 2009 Apr; 113(16):3735-43. PubMed ID: 19109559
[TBL] [Abstract][Full Text] [Related]
38. Human immunoglobulin G hinge regulates agonistic anti-CD40 immunostimulatory and antitumour activities through biophysical flexibility.
Liu X; Zhao Y; Shi H; Zhang Y; Yin X; Liu M; Zhang H; He Y; Lu B; Jin T; Li F
Nat Commun; 2019 Sep; 10(1):4206. PubMed ID: 31562320
[TBL] [Abstract][Full Text] [Related]
39. Characterization of IgG1 Fc Deamidation at Asparagine 325 and Its Impact on Antibody-dependent Cell-mediated Cytotoxicity and FcγRIIIa Binding.
Lu X; Machiesky LA; De Mel N; Du Q; Xu W; Washabaugh M; Jiang XR; Wang J
Sci Rep; 2020 Jan; 10(1):383. PubMed ID: 31941950
[TBL] [Abstract][Full Text] [Related]
40. Design and characterization of novel dual Fc antibody with enhanced avidity for Fc receptors.
Goulet DR; Zwolak A; Williams JA; Chiu ML; Atkins WM
Proteins; 2020 May; 88(5):689-697. PubMed ID: 31702857
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
